Can The UK Remain A First Launch Market?
Uncertainty, Modifiers and Discounts Key To NICE Methods Update
Executive Summary
More political support from the National Health Service and health ministers is needed to ensure the UK’s future as a desirable launch market.
You may also be interested in...
UK MHRA Aims To Cast Early Access Scheme In New Light
The UK’s Early Access to Medicines Scheme continues to provide important flexibility, but companies also now have the option of a new ambitious pathway launched this year for accelerating time to market for innovative medicines.
Global Boardrooms Sceptical About Potential For UK To Be Lifesciences Superpower
The UK has the potential to fulfill its ambition of being a global superpower in life sciences, but it must not get lost in an echo chamber, says a senior MSD executive.
UK Spinraza Data Review Shows Benefits Of NICE Flexibility
Biogen has described as “exciting” a first-of-a-kind interim data review that has led to expanded recommendations for the company’s spinal muscular atrophy drug Spinraza.